SARS-CoV-2 Ab Test
The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Test benefits
The LumiraDx SARS-CoV-2 Ab Test is designed to be used in community care settings to identify individuals with an adaptive immune response to COVID-19, indicating recent or prior infection.
- Easy to implement in point of care settings
- Clinical agreement (direct fingerstick) in samples collected more than 8 days post RT-PCR
- 100% (62/62) positive agreement
- 100% (54/54) negative agreement
- Time to result in 11 minutes
Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B
In this application note, the performance of the LumiraDx SARS-CoV-2 & Flu A/B Test was evaluated versus RT-PCR using anterior nasal swabs from symptomatic patients. The LumiraDx SARS-CoV-2 & Flu A/B Test is an automated, rapid, microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
Correlation of the LumiraDx SARS-CoV-2 antibody Test to other SARS-CoV-2 antibody tests and to viral neutralization
In this poster, LumiraDX shows the interpretative correlation of the rapid, point-of-care LumiraDx SARS-CoV-2 Antibody Test to the Mt. Sinai Hospital COVID-19 ELISA IgG Antibody Test and to viral neutralization.
